Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Recent Articles
A Day in the Life: Transfusion Medicine as Team Sport
In this edition, Justin Kreuter, MD, takes a break from teaching and clinical duties to walk us through a typical day in the life...
Why Are Individuals with Blood Group A at Higher Risk of COVID-19?
New findings published in Blood Advances suggest that SARS-CoV-2, the virus responsible for COVID-19, is particularly drawn to a blood A group antigen on...
Editor’s Corner: All Those YESterdays
A few weeks ago, I was on a Zoom call with a candidate interviewing for a faculty position. The topic of work-life balance came...
New Children’s Hospital Coalition Aims to Combat Pandemic-Driven Drug Shortages
Eleven children’s hospitals have teamed up to form The Children’s Hospital Coalition, aimed at mitigating the effects of drug shortages caused by the COVID-19...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.